Emma Navarro out for rest of year to focus on health issues - ESPN

American Emma Navarro says she has gained her "life back" after opening up on long-running health problems that caused significant weight loss, fatigue, dizziness and left her "feeling deep internal anger" on the court. Navarro, who claimed her first title in more than a year at the Strasbourg Open in May, is currently ranked 24th in the world. The 25-year-old was as high as eighth in 2024, the year she reached the quarter-finals at the Australian Open and Wimbledon, and the last four at the US Open in her native New York. But towards the end of 2025 she was diagnosed with relative energy deficiency in sport (RED-S) and subsequently found out she was suffering with the autoimmune disorder Hashimoto's hypothyroidism. Those issues contributed to her losing nine of her first 13 matches in 2026 and withdrawing from the Charleston Open at the end of March. She says she initially ignored problems that dogged her for three years due to exceeding her expectations on the court. "Being new to professional tennis, I was doing what my team and I thought was best, and pushing myself to the limit was always my MO," she wrote in a lengthy post on Instagram., external"And it worked.

Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.

The new treatment kills off a sub-group of fat cells. (Jian Fan/iStockphoto/Getty Images) Early clinical trials into a new fat reduction treatment have reported promising results, and the treatment takes a more unusual approach: Rather than shrinking fat cells, as most weight loss strategies do, it safely and naturally kills them off. The drug here is CBL-514, which is administered via injection. As well as proving effective at reducing subcutaneous fat (just below the skin), there's evidence it can also reduce visceral fat (stored deeper around the organs). According to the team behind the trials, CBL-514 and its unconventional strategy have the potential to reduce fat in key areas of the body – with further benefits that come with weight loss likely to follow. "We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss," says endocrinologist Timothy Garvey, from the University of Alabama at Birmingham, who headed up the trial.